透析患者的宽QRS波心动过速不一定是高钾血症
本文报告一例62岁透析男性,因门诊心动过缓和低血压就诊,急诊出现宽QRS波心律,心率76-127次/分。前一日已停用氟卡尼和美托洛尔并透析出院。经验性按高钾血症治疗,钙剂无显著心电图改变,碳酸氢钠效果存疑,血钾4.6 mmol/L。氟卡尼水平2.1 μg/ml(正常<1 μg/ml)。尽管已停药和透析,因氟卡尼分布容积大和亲脂性仍发生中毒。提示急诊医生应警惕氟卡尼中毒,避免利多卡因和普鲁卡因胺,尽早用碳酸氢钠,严重病例可考虑胺碘酮、脂肪乳和ECMO。
要点
- 透析患者宽QRS波心动过速对钙剂无反应时,应怀疑非高钾血症所致,需回顾家庭用药(如氟卡尼)。
- 氟卡尼中毒可表现为心动过缓或室性心动过速,即使已停药和透析仍可因分布容积大和亲脂性而持续中毒。
- 怀疑氟卡尼中毒时,应避免利多卡因和普鲁卡因胺,以防进一步钠通道阻滞。
- 应尽早给予碳酸氢钠治疗宽QRS波;严重病例可考虑胺碘酮、脂肪乳和ECMO。
- 本例氟卡尼水平2.1 μg/ml(正常<1 μg/ml),血钾4.6 mmol/L,钙剂无显著心电图改变。
适用人群与场景
- 透析患者出现宽QRS波心动过速或心动过缓、低血压时,尤其有氟卡尼用药史者。
诊断标准与关键阈值
- 氟卡尼中毒诊断依据:氟卡尼血药浓度2.1 μg/ml(正常<1 μg/ml),结合宽QRS波心律和用药史。
- 血钾4.6 mmol/L,不支持高钾血症为宽QRS波原因。
处置流程与药物剂量
- 第一步:怀疑氟卡尼中毒时,避免使用利多卡因和普鲁卡因胺,以防进一步钠通道阻滞。
- 第二步:尽早给予碳酸氢钠治疗宽QRS波(原文未提及具体剂量、途径和频次)。
- 第三步:严重病例可考虑胺碘酮、脂肪乳和ECMO(原文未提及具体剂量和方案)。
- 经验性按高钾血症治疗时,钙剂无显著心电图改变、碳酸氢钠效果存疑,应重新评估病因。
红旗征与不能漏的情况
- 宽QRS波心动过速对钙剂无反应,提示可能不是高钾血症所致,需警惕氟卡尼中毒。
- 氟卡尼中毒死亡率高,需早期识别和治疗。
- 即使已停用氟卡尼并透析,仍可因分布容积大和亲脂性而发生中毒。
研究设计与关键结果
- 病例报告:62岁透析男性,因心动过缓和低血压就诊,急诊出现宽QRS波心律,心率76-127次/分。
- 前一日已停用氟卡尼和美托洛尔并透析出院;急诊经验性按高钾血症治疗,钙剂无显著心电图改变,碳酸氢钠效果存疑。
- 血钾4.6 mmol/L,氟卡尼水平2.1 μg/ml(正常<1 μg/ml)。
- 心律在窦性心律和宽QRS波心动过速之间波动。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:单病例,证据等级低,结论需谨慎推广。
对床旁实践的改变
- 透析患者宽QRS波心动过速时,不应默认高钾血症,需回顾家庭用药(如氟卡尼)。
- 对钙剂无反应的宽QRS波,应怀疑氟卡尼中毒,避免利多卡因和普鲁卡因胺。
- 怀疑氟卡尼中毒时,尽早用碳酸氢钠;严重病例可考虑胺碘酮、脂肪乳和ECMO。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Flecainide is a commonly used IC antiarrhythmic. Clinical presentations of Flecainide toxicity are not commonly described.
CASE REPORT: A 62 year old man on dialysis presented for evaluation of outpatient bradycardia and hypotension. In the ED, patient had wide-complex rhythm with heart rates ranging from 76 to 127. The previous day, Flecainide and Metoprolol were discontinued and patient was dialyzed and discharged. The patient was treated empirically for possible hyperkalemia. No significant change in ECG was noted with administration of calcium. Sodium bicarbonate produced questionable benefit. Potassium level was 4.6 mmol/L. Cardiac rhythm fluctuated between sinus rhythm and wide complex tachycardia in the ED & ICU. Flecainide level was 2.1 μg/ml (normal <1 μg/ml). Toxicity developed despite previous discontinuation and dialysis prior to presentation because of Flecainide's large volume of distribution and lipopholicity. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Although Flecainide toxicity is uncommon, it has a high mortality rate, requiring early identification and treatment. Flecainide toxicity can develop in patients with hepatic or renal insufficiency, and can manifest with ventricular tachycardia or bradycardia. If suspicion of Flecainide toxicity arises, lidocaine and procainamide should be avoided to prevent further sodium channel blockade. Absence of response to calcium for a very wide complex QRS should raise clinicians' suspicion that WCT is not due to hyperkalemia, emphasizing the importance of reviewing patients' home medications. Sodium bicarbonate should be administered early to treat widened QRS. Amiodarone, intralipid emulsion therapy and ECMO may be considered in severe cases.
参考来源
- Hoang K, Pazderka P, Hakmeh W, et al. Wide complex tachycardia in dialysis patients is not always hyperkalemia. Am J Emerg Med. 2021. PMID: 34391584. doi:10.1016/j.ajem.2021.08.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。